Natixis Advisors
EBS icon

Natixis Advisors’s Emergent Biosolutions EBS Stock Holding History

Natixis Advisors’s Portfolio EBS Stock Details EBS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-42,911
Closed -$1.87M – 1434
2021
Q4 		$1.87M Buy
42,911
+7,409
+21% +$335K 0.01% 967
2021
Q3 		$1.78M Sell
35,502
-1,757
-5% -$106K 0.01% 944
2021
Q2 		$2.35M Sell
37,259
-18,739
-33% -$1.2M 0.01% 861
2021
Q1 		$5.2M Sell
55,998
-9,631
-15% -$986K 0.03% 583
2020
Q4 		$5.88M Buy
65,629
+26,097
+66% +$2.4M 0.03% 497
2020
Q3 		$4.08M Sell
39,532
-1,589
-4% -$171K 0.03% 576
2020
Q2 		$3.25M Sell
41,121
-11,453
-22% -$853K 0.02% 650
2020
Q1 		$3.04M Buy
52,574
+21,538
+69% +$1.24M 0.02% 619
2019
Q4 		$1.67M Sell
31,036
-18,691
-38% -$1.01M 0.01% 849
2019
Q3 		$2.6M Buy
49,727
+5,577
+13% +$260K 0.02% 695
2019
Q2 		$2.13M Buy
44,150
+5,874
+15% +$282K 0.02% 757
2019
Q1 		$1.93M Buy
+38,276
New +$2.26M 0.02% 768

Other funds holding EBS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

Natixis Advisors's EBS Position: Q1 2022 in Review

Natixis Advisors sold out of Emergent Biosolutions (EBS) in Q1 2022, closing a stake of 42,911 shares — an estimated $1.87M sold.

Natixis Advisors first reported a position in EBS in Q1 2019 and held it in 12 quarters. The position peaked at $5.88M in Q4 2020. 255 funds tracked by Wall St. Rank hold EBS as of Q1 2022.

  • Natixis Advisors reported no remaining Emergent Biosolutions position as of Q1 2022 after selling out during the quarter.
  • Natixis Advisors sold 42,911 Emergent Biosolutions shares in Q1 2022, an estimated $1.87M.
  • Natixis Advisors first reported a position in Emergent Biosolutions in Q1 2019 and held it in 12 quarters.
  • Natixis Advisors's Emergent Biosolutions position peaked at $5.88M in Q4 2020.
  • 255 funds tracked by Wall St. Rank held Emergent Biosolutions as of Q1 2022.

Based on Natixis Advisors's 13F filing for Q1 2022, filed 12 May 2022.